Abstract
Introduction: Despite the effects of statins on reduction of LDL-cholesterol (LDL-C) and coronary plaque progression, significant residual cardiovascular (CV) risk persists in patients with elevated triglycerides (TGL). Icosapent ethyl (IPE) as an adjunct to statins was shown to significantly reduce adverse CV events in patients with residual hypertriglyceridemia. The EVAPORATE trial showed that IPE significantly reduced progression of Total Plaque (TP) and Total Non Calcified plaque (TNCP), assessed by serial CCTA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
